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identified at IMSS and 631 at ISSSTE, 2,570 and 536 of them with NSCLC. A 4.2% ALK+ 
rate was assumed. Direct medical costs of standard treatment for LC were obtained 
from a published source. Cost for crizotinib was given by the manufacturer. All costs 
are expressed in 2014 USD ($1USD= $13MXN). Two scenarios are presented: 1) world 
without crizotinib, where all patients with LC are treated with standard treatment; 2) 
world with crizotinib, where patients with ALK+ advanced NSCLC are treated with 
crizotinib and all other LC patients are treated with standard treatment. Results: 81 
and 17 ALK+ advanced NSCLC patients were identified in IMSS and ISSTE, respectively. 
Total costs in a world “without” and “with” crizotinib using a one-year time horizon is 
$50.3 and $52.9 million, respectively, for IMSS. For ISSSTE, total costs were $10.5 versus 
$11.1 million. The combined incremental budget impact across both public health care 
institutions is 5.2%. ConClusions: Crizotinib, the only drug approved for the treat-
ment of ALK+ advanced NSCLC patients has a minimal incremental budget impact on 
the overall expenditure within the two main Mexican public health care institutions.
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objeCtives: To estimate the budget impact of everolimus-exemestane versus the 
most commonly used regimens in the Egyptian practice; gemcitabine-paclitaxel 
and capecitabine-docetaxel for a health care plan that introduces everolimus 
for post-menopausal hormone receptor positive, human epidermal growth fac-
tor receptor-2 negative metastatic breast cancer (HR+, HER2-MBC) patients over 
three years. Methods: Drug and medical budget impacts (2013 EGP) were esti-
mated over the first three years of the three drug regimens use from the health 
insurance perspective. Epidemiology data were used to estimate target popula-
tion size. The treatment data for MBC patients were obtained from published and 
nonpublished sources. The model considered 2 scenarios—without (pre) and with 
(post) everolimus-exemestane. Monthly medical costs were calculated for 
the pre- and post-progression phase. Results were considered on a per member 
per month (PMPM) basis to examine the relative impact on the plan. Deterministic 
sensitivity analyses were conducted. Results: In a real-world 6,055,902 targeted 
patients, 288,261 of them were found to be candidates for everolimus-exemestane 
regimen. For patients taking gemcitabine-paclitaxel and capecitabine-docetaxel 
regimens, the estimated incremental cost PMPM was LE3.00 and LE2.94 respec-
tively for each after three years. The estimated incremental cost PMPM for the 
gemcitabine-paclitaxel population was LE0.62, LE2.60 and LE5.77 for year 1, 2 and 
3 respectively while for the capecitabine-docetaxel population was LE0.59, LE2.54 
and LE5.70 for year 1, 2 and 3 respectively. The capecitabine-docetaxel results 
were most sensitive to the cost of everolimus while gemcitabine-paclitaxel results 
were most sensitive to the number of eligible patients. ConClusions: Increased 
acquisition costs of everolimus-exemestane for HR+, HER2-MBC treatment 
are expected to be obviously offset by both the reduced number of progressed patients 
and the relatively small medical costs due to avoided adverse events of each of gem-
citabine-paclitaxel and capecitabine-docetaxel regimens. The expected budget impact 
of covering everolimus for this group of patients was relatively small.
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bACkgRound: Chronic Lymphocytic Leukemia (CLL) is a malignant disease incur-
able of the lymphoid system, that affects predominantly elderly, especially in 
Western countries. Your treatment when necessary is based on the administration 
of chemotherapy, with association of fludarabine plus cyclophosphamide (FC), the 
most widely used schema. Recently the addition of rituximabe, a monoclonal anti-
body has been associated with this scheme, known as FCR. objeCtives: To elabo-
rate a budget impact analysis (BIA) of rituximab for chronic lymphocytic leukemic 
for help the decision making. Methods: A BIA of association of fludarabine plus 
cyclophosphamide in SUS compared to rituximab with this scheme was performed. 
The analysis’ time horizon was 5 years, using a CLL prevalence of 4.4% and 25% of 
CLL refractory between them (1.634), considering an annual growth rate of 0.8143% 
and a market share of 25% and 75% according the classification of diagnosis and 
stage of Rai & Keating. The mean total rituximab dose considered was 375/mg/
m2, with an average personal weight and size of 70kg and 1,70m, which means 
681,75mg per cicle. All cost purchase prices and remission rate of rituximab (22%) 
and stand chemiterapy (9%) were obtained at one year trial in the onco-hematol-
ogy high complexity Clinical Hospital of the Faculty of Medicine of Ribeirão Preto 
HCFMRP / USP hospital measured in real 2012. Results: The budget impact of FC 
per year would be 38.7m reais ($17.5m) in the 1st year, considering 25% of target 
population, reaching approximately 135.3m reais ($60.9m) in 75% of patients. For 
RFC, the budget impact would be 97 million reais ($43.6m) in the 1st year, reaching 
340 million reais ($153m) in 75% of patients. ConClusions: Treatment costs still 
impressive, considering that rituximab ’ values reach 2.5 times the clicle unit values 
of standart chemioperapy, fact that did not happen in other countries where they 
are already covered.
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by targeting prophylaxis based on patient genotype. The deterministic sensitivity 
analysis showed that the savings is most dependent on the incidence of invasive 
fungal infection, cost of treating an invasive fungal infection, and frequency of *17 
in the population. ConClusions: Genotyping AML patients for CYP2C19*17 prior to 
induction-consolidation is expected to be cost-neutral or potentially cost-saving by 
reducing the incidence of invasive fungal infections compared to standard prophy-
laxis. These results may mitigate potential budgetary concerns, thereby reducing 
barriers to a test that can be clinically beneficial to AML patients.
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objeCtives: In the latest years several drugs demonstrated to increase survival 
in mCRPC patients post chemotherapy failure. However, issues remain related to 
the treatment sequencing of these drugs. The aim of this study is to estimate the 
budget impact of the introduction of enzalutamide in the Brazilian Private Health 
System. Methods: A deterministic state transition budget impact model (BIM) 
was developed to estimate treatment costs of mCRPC patients after chemotherapy 
failure over a 3-year time horizon. Budget impact was estimated comparing a base-
line scenario including mandatory coverage drugs (abiraterone, cabazitaxel) with 
an alternative scenario including all treatment options (abiraterone, cabazitaxel 
and enzalutamide). Target population, dosing, duration of therapy and sequenc-
ing was based on scientific literature. Pharmaceutical direct costs were based on 
factory price, assuming parity price of enzalutamide and abiraterone. Univariate 
Deterministic sensitivity analysis was conducted to determine the impact of param-
eters on results. Results: The BIM estimates that a total of 5,789 patients will be 
treated in the next three years, with annual cost estimates in the baseline scenario 
of R$83,944,041 in year 1, reaching R$198,507,065 in year 3 of the simulation. The 
introduction of enzalutamide would incur a total increase in costs of R$16,649,325 
after 3 years. In deterministic sensitivity analysis, enzalutamide price, proportion of 
patients receiving additional treatment line and duration of therapy were the most 
important variables that impacted results, with the alternative scenario remaining 
more costly than the baseline scenario in all simulations, incurring additional costs 
ranging from R$6,634,955 to R$38,818,233. ConClusions: Considering current 
available evidence regarding treatment sequencing, the introduction of enzaluta-
mide is expected to increase costs to the Brazilian Private Health System.
PCN47
Budget ImPaCt model of CePleNe® as maINteNaNCe theraPy IN adult 
PatIeNts WIth aCute myeloId leukemIa IN fIrst remIssIoN
Kaskens L.1, Gehenio D.2, Munzel U.2, Darba J.3
1BCN Health Economics & Outcomes Research S.L., Barcelona, Spain, 2Meda Pharma GmbH & Co 
KG, Bad Homburg vor der Höhe, Germany, 3Universitat de Barcelona, Barcelona, Spain
objeCtives: To assess the economic impact of Ceplene® with low-dose Interleukin-2 (IL-2) 
for the treatment of adult patients with Acute Myeloid Leukemia (AML) in first complete 
remission (CR-1) which previously received intensive chemotherapy in Spain. Methods: 
A budget impact model was developed using the perspective of the Spanish 
National Health System with a 4-year time horizon. Ceplene®/IL-2 was compared 
with no treatment and an unrelated allogenic hematopoietic stem cell transplant 
(allo-HSCT). For both treatment options and no treatment, health care costs (EUR 
2013) including medical visits, hospitalisations, laboratory and diagnostic tests, 
prophylactic measures, treatment of complications and infections were consid-
ered. Average treatment costs per patient up to a maximum of three years were 
estimated for both treatment options and no treatment depending on the prob-
ability of overall survival without or with a relapse, and death without relapse, as 
well as the duration until relapse or death without relapse during this period. Total 
annual health care costs were estimated based on the annual per patient cost, the 
target population, and the market shares associated with each option, before and 
after the introduction of Ceplene®/IL-2. Results: Patients eligible for Ceplene®/
IL-2 were estimated at 1,502 in 2013 with a small increase up to 1,509 in 2016. 
The overall budget impact with the introduction of Ceplene®/IL-2, is estimated to 
decrease with € 674,149 and € 728,945 in 2014 and 2016, and an increase of € 202,322 
in 2015. Overall budget impact savings over the period 2014-2016 are estimated at 
€ 1,130,894. ConClusions: The introduction of Ceplene®/IL-2 as maintenance therapy 
supposes savings in the budget impact for the treatment of AML patients in CR-1 in Spain. 
Ceplene®/IL-2 is expected to fulfil a direct medical need for patients not eligible or having 
an unfavourable profile for an unrelated allo-HSCT receiving no treatment, and those who 
received an unrelated allo-HSCT with unfavourable prognostics.
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objeCtives: Standard treatment for lung cancer (LC) in Mexico is chemotherapy. 
Crizotinib is the only therapy approved for patients with ALK+ advanced non-small 
cell lung cancer (NSCLC), a low prevalence condition. This analysis aims to estimate 
the economic impact of using crizotinib for patients with ALK+ advanced NSCLC 
in the Mexican setting from public health care institution perspective. Methods: 
A budget impact analysis with a one-year time horizon was developed to compare 
expected costs that the Mexican Social Security Institute (IMSS) and the Safety and 
Social Services for State Workers Institute (ISSSTE) public health care institutions 
would incur if they were to include crizotinib on their formularies. Using epidemiol-
ogy data from published sources, a total of 3,023 potential patients with LC were 
